USANA HEALTH SCIENCES INC. overview

USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal second quarter ended July 1, 2023. Key Financial & Operating Results Second quarter net sales were $238 million versus $264 million during the second quarter of 2022. Second quarter diluted EPS was $0.89 as compared with $1.00 during the second quarter of 2022. Fiscal 2023 net sales and diluted EPS guidance updated to $900 to $950 million and $2.65 to $3.30, respectively, from $875 million to $950 million...

USANA Health Sciences, Inc. (NYSE:USNA) today announced that second quarter results will be released after the close of market on Tuesday, July 25, 2023. Shortly following the issuance of the Company’s earnings release, the Company will post its Management Commentary document on the Company’s Investor Relations website ( http://ir.usana.com ) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following...

USANA Health Sciences, Inc. (NYSE: USNA) today announced its plans to expand into India in the second half of 2023. Expansion into India increases the Company’s global footprint to 25 markets. “USANA’s expansion into India is our first new market in five years and provides an exciting and gratifying opportunity to introduce USANA’s world class health and wellness products to a new country, culture and demographic,” said Jim Brown, President. “We have spent several years of extensive...

USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended April 1, 2023. Key Financial & Operating Results First quarter net sales were $248 million versus $228 million for the fourth quarter of 2022 and $273 million during the first quarter of 2022. First quarter diluted EPS was $0.95 as compared with $0.66 for the fourth quarter of 2022 and $1.15 during the first quarter of 2022. Generated $13 million of operating cash flow during the...

USANA Health Sciences, Inc. (NYSE:USNA) today announced that first quarter results will be released after the close of market on Tuesday, April 25, 2023. Shortly following the issuance of the Company’s earnings release, the Company will post its Management Commentary document on the Company’s Investor Relations website ( http://ir.usana.com ) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following...

USANA Health Sciences, Inc. (NYSE:USNA), a leading developer and manufacturer of high-quality nutritional supplements, healthy foods and personal care products, today announced that Doug Hekking, Chief Financial Officer, is scheduled to participate in upcoming investor conferences. Details for each event are as follows: 35 th Annual Roth Conference Monday, March 13, 2023 1x1 Investor Meetings Dana Point, CA D.A. Davidson Consumer Growth Conference Tuesday, March 21, 2023 1x1 Investor Meetings...

USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal fourth quarter and full year ended December 31, 2022. Key Financial & Operating Results Fourth quarter net sales were $228 million versus $267 million during the prior-year period. Fourth quarter diluted EPS was $0.66 as compared with $1.03 during Q4 2021. Fiscal year 2022 net sales were $999 million as compared with $1,186 million during fiscal year 2021. Fiscal year 2022 diluted EPS totaled $3.59 versus...

USANA Health Sciences, Inc. (NYSE: USNA) today announced preliminary fiscal year 2022 results and initial guidance for fiscal year 2023 ahead of its presentation at the 25 th Annual ICR Conference. The Company currently anticipates fiscal year 2022 net sales of approximately $995 million and diluted earnings per share of approximately $3.65. The Company’s most recently issued fiscal year 2022 guidance anticipated net sales between $955 and $975 million and diluted earnings per share between...